2016 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Seminar

 描述（由申请人提供）：我们请求部分支持2016年脂蛋白代谢戈登研究会议（GRC）和戈登研究研讨会（GRS）将于2016年6月12日至17日在新罕布什尔州的沃特维尔谷会议中心举行。主席约翰·帕克斯博士与前任主席、2016年联合主席（Alan Remaley博士和Cheryl惠灵顿博士）以及该领域的领导人为GRC计划了九次口头会议：第1节-脂质转运和血管紧张素转换酶，第2节-脂蛋白和血管壁，第3节-脂蛋白代谢和冠心病的主题演讲和简短演讲，第4节-脂质代谢的体内生理学，第5节-肝脏和肠道脂质/脂蛋白代谢，第6节- HDL功能，第7节-脂质/脂蛋白代谢的遗传学，第8节-细胞内脂质代谢，和第9节-心血管和神经退行性疾病的治疗。在GRC之前，脂蛋白代谢GRS是一个国际论坛，用于研究生和博士后研究员介绍和讨论前沿研究。我们的会议满足NHLBI使命的各个方面。1)我们汇集了脂蛋白代谢领域的国际领导者，脂蛋白代谢是一个生理过程，占全球心血管风险负担的30%以上。2)性别和多样性相关的遗传学，生物学，生物化学和脂蛋白的临床表现的问题也得到了解决，承认这些问题的复杂性。此外，在33名被接受的发言人中，有13名是妇女（39%），包括主旨发言人海伦·霍布斯博士，一名是非洲裔美国人（3%），3名（9%）是年轻的调查人员。此外，八个被接受的发言人是国际性的，代表美国以外的六个国家。3)我们的会议经过精心协调，包括与血脂异常，心血管疾病和其他慢性疾病（如胰岛素抵抗，阿尔茨海默病和脂肪肝）的原因，预防，诊断和治疗相关的各种研究。4)为了与NHLBI的预防优先级保持一致，我们在过去的会议上首次报告了目前常规临床使用的心血管疾病一级和二级预防的关键方面（例如他汀类药物）。5)主席和共同主席高度重视个人在培训和职业发展初期的参与。 叙述：2016年脂蛋白代谢戈登研究会议将汇集脂蛋白代谢的国家和国际领导者，这是全球心血管疾病风险负担的30%以上，这是一个关键的主题。

 DESCRIPTION (provided by applicant): We request partial support for the 2016 Lipoprotein Metabolism Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held at Waterville Valley Conference Center in New Hampshire on June 12-17, 2016. The Chair, Dr. John Parks, in consultation with past chairs, the 2016 Co-Chairs (Drs. Alan Remaley and Cheryl Wellington), and leaders in the field, have planned nine oral sessions for the GRC: Session 1- Lipid Transport and Catabolism, Session 2- Lipoproteins and the Vascular Wall, Session 3- Keynote Address on Lipoprotein Metabolism and Coronary Heart Disease and short talks, Session 4- In vivo Physiology of Lipid Metabolism, Session 5- Liver and Intestinal Lipid/Lipoprotein Metabolism, Session 6- HDL function, Session 7- Genetics of Lipid/Lipoprotein Metabolism, Session 8- Intracellular Lipid Metabolism, and Session 9- Therapeutics for Cardiovascular and Neurodegenerative Diseases. The GRC will be preceded by the Lipoprotein Metabolism GRS, an international forum for the presentation and discussion of cutting-edge research by graduate students and postdoctoral fellows. Our conference satisfies all aspects of the NHLBI mission. 1) We bring together international leaders in lipoprotein metabolism, a physiological process that accounts for more than 30% of global cardiovascular risk burden. 2) Gender and diversity-related issues in genetics, biology, biochemistry, and clinical manifestations of lipoproteins are also addressed, acknowledging the complexity of these issues. Also, 13 of the 33 accepted speakers are women (39%), including the Keynote Speaker, Dr. Helen Hobbs, one is African American (3%), and 3 (9%) are young investigators. In addition, eight of the accepted speakers are international, representing six countries outside the US. 3) Our conference has been carefully coordinated to include a diversity of research related to the causes, prevention, diagnosis and treatment of dyslipidemias, cardiovascular disease, and other chronic diseases, such as insulin resistance, Alzheimer's disease, and hepatosteatosis. 4) In keeping with the NHLBI's priority on prevention, key aspects of primary and secondary prevention of cardiovascular disease currently in routine clinical use (e.g. statin drugs) were firt reported at our past meetings. 5) The Chair and Co-Chairs place the highest priority on participation by individuals early in their training and career development. Narrative: The 2016 Lipoprotein Metabolism Gordon Research Conference will bring together national and international leaders in lipoprotein metabolism, which underlies more than 30% of the global risk burden of cardiovascular disease, a subject of critical